Skip to Main Content

SAN DIEGO — A Biogen executive had just finished presenting slides on the company’s resurrected Alzheimer’s drug at a medical meeting here on Thursday, and now it was time for the panel of experts up on stage to weigh in on whether they found the data convincing.

They did. In fact, they positively gushed. One of the experts called the data “exhilarating.” Another deemed it “a hugely important result.” A third heralded “a milestone achievement for our field.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!